Head-To-Head Analysis: EnteroMedics (RSLS) versus Its Competitors

EnteroMedics (NASDAQ: RSLS) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare EnteroMedics to similar businesses based on the strength of its dividends, risk, institutional ownership, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares EnteroMedics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
EnteroMedics $790,000.00 -$23.36 million -0.23
EnteroMedics Competitors $2.14 billion $229.91 million -29.85

EnteroMedics’ rivals have higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

0.8% of EnteroMedics shares are held by institutional investors. Comparatively, 50.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 26.4% of EnteroMedics shares are held by company insiders. Comparatively, 18.3% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

EnteroMedics has a beta of 3.09, indicating that its stock price is 209% more volatile than the S&P 500. Comparatively, EnteroMedics’ rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for EnteroMedics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EnteroMedics 0 0 1 0 3.00
EnteroMedics Competitors 271 1886 3394 108 2.59

EnteroMedics presently has a consensus price target of $11.03, suggesting a potential upside of 729.32%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.47%. Given EnteroMedics’ stronger consensus rating and higher probable upside, equities analysts clearly believe EnteroMedics is more favorable than its rivals.


This table compares EnteroMedics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EnteroMedics -4,509.61% -104.23% -90.59%
EnteroMedics Competitors -311.02% -24.15% -9.64%


EnteroMedics rivals beat EnteroMedics on 7 of the 12 factors compared.

About EnteroMedics

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply